CE Disclosures and Faculty Information

• OVERVIEW OF ACTIVITY
  
  Multiple myeloma (MM) is a plasma cell neoplasm that accounts for approximately 10% of all hematologic cancer cases and carries with it the worst death to new cases ratio (3:4) of all the blood cancer subtypes. Patients with smoldering (asymptomatic) myeloma may simply be observed, as they often experience an indolent course for many years without therapy. However, patients with more advanced, active disease require immediate induction therapy in an effort to prepare eligible candidates for autologous stem cell transplant (ASCT). Optimal initial induction therapy for both non-ASCT and ASCT candidates remains an area of clinical controversy, and currently one must consider multiple acceptable treatment options. Recent clinical research demonstrates an abundance of treatment options now available to patients with both newly diagnosed and relapsed or refractory MM.
   
  In April 2011 a 2-day MM working group summit was convened, comprising 19 myeloma clinical investigators, 17 community-based hematologists/oncologists and 2 nurse practitioners who care for patients with MM. This unique, case-based audio activity highlights key commentary from the meeting and is designed to assist practicing hematologists/oncologists in formulating up-to-date clinical management strategies for MM.
  
  LEARNING OBJECTIVES
  
  • Appraise recent data on therapeutic advances and changing practice standards in MM, and apply this information to clinical practice.
  • Use biomarkers to assess risk for patients with MM, and recommend systemic treatment commensurate with prognosis and likelihood of therapeutic response in the induction, consolidation or maintenance setting.
  • Recognize and apply essential patient care considerations that enable the successful delivery of bortezomib- and/or IMiD-containing systemic therapy for MM.
  • Prevent or mitigate bortezomib- and/or IMiD-related neurologic, dermatologic and thromboembolic complications in patients receiving systemic therapy for MM.
  • Consider emerging evidence on bone-targeted therapy, and apply it to clinical decisions regarding choice, duration and frequency of administration of these agents for patients with MM.
  • Identify patients with MM who may experience quantitative and qualitative benefit from stem cell transplantation, and counsel them appropriately.
  • Offer evidence-based supportive management strategies and/or dose adjustments to globally facilitate tolerability of and adherence to systemic treatments for MM.
  • Recall emerging efficacy and safety data with newer-generation IMiDs and proteasome inhibitors currently under investigation in MM.
  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  CME credit is no longer available for this issue
  
  This CME activity contains an audio component. The participant should listen to the audio MP3s.
  
  CONTENT VALIDATION AND FACULTY DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Alsina — Advisory Committee: Millennium: The Takeda Oncology Company; Paid Research: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Anderson — Advisory Committee and Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc. Dr Bensinger — Advisory Committee: Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Consulting Agreement: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genzyme Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation. Dr Borrello — Advisory Committee and Speakers Bureau: Celgene Corporation. Dr Fonseca — Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Lilly USA LLC, Medtronic Inc, Otsuka Pharmaceutical Co Ltd; Paid Research: Celgene Corporation, Onyx Pharmaceuticals Inc. Dr Gasparetto — Advisory Committee: Celgene Corporation; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Gertz — Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Huff — Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson Pharmaceuticals, Onyx Pharmaceuticals Inc; Paid Research: Bristol-Myers Squibb Company, Geron. Dr Lonial — Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc. Dr Munshi — Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr Niesvizky — Advisory Committee, Consulting Agreements and Paid Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Palumbo — Advisory Committee and Consulting Agreements: Amgen Inc, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr Siegel — Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Stadtmauer — Advisory Committee: Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Pfizer Inc; Consulting Agreement: GlaxoSmithKline; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Dr Stewart — Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Paid Research: Millennium: The Takeda Oncology Company. Dr Tricot — Paid Research: Biotech Pharmaceuticals, Otsuka Pharmaceutical Co Ltd. Dr Vij — Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Eisai Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr Wolf — Speakers Bureau: Celgene Corporation, Centocor Ortho Biotech Services LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr Zonder — Consulting Agreements: Amgen Inc, Medtronic Inc; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company.
  
  ADDITIONAL PRACTITIONER DISCLOSURES
  
  Drs Feinstein, Fusselman, Glynn, Greenfield, Lobins, Mancusi-Ungaro, Melear, Morganstein, Robbins, Schwartz and Simmons had no real or apparent conflicts of interest to disclose. The following community practitioners (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Ms Bilotti — Advisory Committee and Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company; Consulting Agreements: Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company. Dr Brenner — Consulting Agreement: Celgene Corporation; Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: Celgene Corporation. Dr Farber — Advisory Committee: Bristol-Myers Squibb Company, Genentech BioOncology, Millennium: The Takeda Oncology Company; Speakers Bureau: Alexion Pharmaceuticals, Allos Therapeutics, Bristol-Myers Squibb Company, Genentech BioOncology, Genzyme Corporation; Stock Ownership: Alexion Pharmaceuticals. Dr Hager — Speakers Bureau: Allos Therapeutics, Novartis Pharmaceuticals Corporation. Dr Lessen — Consulting Agreement: Spectrum Pharmaceuticals Inc; Speakers Bureau: GlaxoSmithKline, Myriad Genetics Inc. Dr Moss — Advisory Committee: Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation; Paid Research: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Pfizer Inc; Speakers Bureau: Amgen Inc, Genomic Health Inc, Novartis Pharmaceuticals Corporation. Dr Peles — Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company. Ms Richards — Consulting Agreement: Millennium: The Takeda Oncology Company; Speakers Bureau: Celgene Corporation.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation and Onyx Pharmaceuticals Inc.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: October 2011
  Expiration date: October 2012